DiaMedica Therapeutics Total Assets Growth & History (DMAC)
DiaMedica Therapeutics's total assets was $61.4M for fiscal 2025.
View full DiaMedica Therapeutics company overviewDiaMedica Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $61.4M | $15.0M | +32.42% |
| 2024 | 2024-12-31 | $46.3M | −$7.8M | −14.43% |
| 2023 | 2023-12-31 | $54.2M | $19.8M | +57.46% |
| 2022 | 2022-12-31 | $34.4M | −$11.2M | −24.49% |
| 2021 | 2021-12-31 | $45.6M | $17.5M | +62.13% |
| 2020 | 2020-12-31 | $28.1M | $19.0M | +210.34% |
| 2019 | 2019-12-31 | $9.1M | −$9.3M | −50.64% |
| 2018 | 2018-12-31 | $18.3M | $16.5M | +917.70% |
| 2017 | 2017-12-31 | $1.8M | — | — |
DiaMedica Therapeutics quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $45.0M | $13.5M | +43.00% |
| Q1 2026 | 2026-03-31 | $53.1M | $14.3M | +36.70% |
| Q4 2025 | 2025-12-31 | $61.4M | $15.0M | +32.42% |
| Q3 2025 | 2025-09-30 | $57.0M | $4.5M | +8.61% |
| Q2 2025 | 2025-06-30 | $31.5M | −$25.3M | −44.59% |
| Q1 2025 | 2025-03-31 | $38.8M | −$10.4M | −21.17% |
| Q4 2024 | 2024-12-31 | $46.3M | −$7.8M | −14.43% |
| Q3 2024 | 2024-09-30 | $52.5M | −$5.6M | −9.66% |
| Q2 2024 | 2024-06-30 | $56.8M | −$5.3M | −8.48% |
| Q1 2024 | 2024-03-31 | $49.3M | $19.0M | +63.02% |
| Q4 2023 | 2023-12-31 | $54.2M | $19.8M | +57.46% |
| Q3 2023 | 2023-09-30 | $58.1M | $21.1M | +56.96% |
| Q2 2023 | 2023-06-30 | $62.0M | $22.8M | +58.06% |
| Q1 2023 | 2023-03-31 | $30.2M | −$12.0M | −28.41% |
| Q4 2022 | 2022-12-31 | $34.4M | −$11.2M | −24.49% |
| Q3 2022 | 2022-09-30 | $37.0M | −$11.6M | −23.88% |
| Q2 2022 | 2022-06-30 | $39.3M | $17.5M | +80.30% |
| Q1 2022 | 2022-03-31 | $42.2M | $17.9M | +73.31% |
| Q4 2021 | 2021-12-31 | $45.6M | $17.5M | +62.13% |
| Q3 2021 | 2021-09-30 | $48.7M | $17.4M | +55.63% |
| Q2 2021 | 2021-06-30 | $21.8M | $9.2M | +73.07% |
| Q1 2021 | 2021-03-31 | $24.4M | $10.0M | +69.55% |
| Q4 2020 | 2020-12-31 | $28.1M | $19.0M | +210.34% |
| Q3 2020 | 2020-09-30 | $31.3M | $20.2M | +183.27% |
| Q2 2020 | 2020-06-30 | $12.6M | −$216,000 | −1.69% |
| Q1 2020 | 2020-03-31 | $14.4M | −$1.1M | −7.29% |
| Q4 2019 | 2019-12-31 | $9.1M | −$9.3M | −50.64% |
| Q3 2019 | 2019-09-30 | $11.0M | — | — |
| Q2 2019 | 2019-06-30 | $12.8M | — | — |
| Q1 2019 | 2019-03-31 | $15.5M | — | — |
| Q4 2018 | 2018-12-31 | $18.3M | $16.5M | +917.70% |
| Q4 2017 | 2017-12-31 | $1.8M | — | — |
DiaMedica Therapeutics total assets trends
Over the last five fiscal years, DiaMedica Therapeutics's total assets increased from $28.1M to $61.4M, a change of $33.3M. The latest reported quarter, Q2 2026, shows $45.0M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review DiaMedica Therapeutics source filings ↗